Company Description
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.
In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient.
The company was incorporated in 2019 and is headquartered in Los Altos, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Amit Etkin |
Contact Details
Address: 369 South San Antonio Road Los Altos, California 94022 United States | |
| Phone | 650 200 0412 |
| Website | altoneuroscience.com |
Stock Details
| Ticker Symbol | ANRO |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001999480 |
| CUSIP Number | 02157Q109 |
| ISIN Number | US02157Q1094 |
| Employer ID | 83-4210124 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, Chief Executive Officer and President |
| Nicholas C. Smith | Chief Financial Officer and Secretary |
| Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Michael C. Hanley M.B.A. | Chief Operating Officer |
| Melissa Berman | Vice President of Finance and Accounting |
| Erin R. McQuade J.D. | General Counsel and Chief Administrative Officer |
| Jessica Powell | Chief Development Officer |
| Fadi Abdel M.D. | Senior Vice President of Innovation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 11, 2025 | EFFECT | Notice of Effectiveness |
| Feb 3, 2025 | 8-K | Current Report |
| Feb 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 16, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |